Compare GEOS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEOS | BOLD |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 54.5M |
| IPO Year | 1997 | 2024 |
| Metric | GEOS | BOLD |
|---|---|---|
| Price | $3.79 | $2.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 83.9K | ★ 162.0K |
| Earning Date | 11-19-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $0.96 |
| 52 Week High | $28.77 | $3.16 |
| Indicator | GEOS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 31.95 | 46.97 |
| Support Level | N/A | $2.37 |
| Resistance Level | $4.80 | $2.65 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 19.95 | 44.44 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.